NORP – Page 3 – Talk Bio

FDA Approves Ono’s Romvimza for Rare Joint Tumor, Challenging Daiichi Sankyo’s Turalio

5 months ago talkbio0Tagged Approved, CSF1, CSF1 gene, Daiichi, Dosage Forms, Fibrous histiocytoma of tendon sheath, Giant Cell Tumors, Inhibitor, Joint Tumor, Romvimza, Sankyo, tenosynovial, Turalio, United States Food and Drug Administration, Vimseltinib

Romvimza, vimseltinib, tenosynovial giant cell tumor (TGCT), Ono Pharmaceutical, FDA approval, Daiichi Sankyo, Turalio, CSF1 inhibitor, rare joint tumor

Bain Capital Acquires Mitsubishi Tanabe Pharma for $3.3 Billion in Strategic Japanese Pharma Investment

6 months ago talkbio0Tagged Acquisition, Bain Capital, carve-out, Drug Industry, Investments, Japanese language, Mitsubishi, Private Equity, Transaction

Bain Capital, Mitsubishi Tanabe Pharma, acquisition, Japanese pharmaceutical industry, carve-out transaction, private equity, life sciences investment

RFK Jr.’s HHS Secretary Nomination Advances to Full Senate Vote

6 months ago talkbio0Tagged CHARGE Syndrome, Confirmation, Republican, Robert F. Kennedy, Secretary, Senate Finance Committee, Vaccines

Robert F. Kennedy Jr., HHS Secretary, Senate Finance Committee, confirmation process, vaccine controversy, Republican support

RFK Jr. Faces Intense Scrutiny in Senate Confirmation Hearings for HHS Secretary

6 months ago talkbio0Tagged Confirmation, doubt, Health, Hearings, Human Services Secretary, Republican, Robert F. Kennedy, Senate, stance, Transplant Registry Unified Management Program, Vaccines

Robert F. Kennedy Jr., Senate confirmation hearings, Health and Human Services Secretary, Trump nominee, vaccine stance, Republican doubts

Pfizer Agrees to $60 Million Settlement Over Nurtec Anti-Kickback Allegations

6 months ago talkbio0Tagged anti-kickback suit, Migraine Disorders, Nurtec, Pfizer, settlement

Pfizer, Nurtec, anti-kickback suit, settlement, Biohaven, migraine medicine

Chinese Vaccine Biotech Ab&B Files for IPO, Drawing Attention from GSK, Merck, and Pfizer

6 months ago talkbio0Tagged Ab&B, Bio-Tech, Biotechnology, Chinese vaccine, Drug Industry, IPO, Pfizer, Pfizer/, SmithKline Beecham

Ab&B Bio-Tech, IPO, Chinese vaccine biotech, GSK, Merck, Pfizer, biotechnology, pharmaceutical industry

Chinese Biotechs Flock to Hong Kong IPOs for Next Growth Phase

6 months ago talkbio0Tagged Bay Area, Biotechnology, Chinese biotechs, Greater, HKEX, IPOs, Kong, listing reforms, Listings

Chinese biotechs, Hong Kong IPOs, biotechnology, pharmaceuticals, listing reforms, HKEX, Chapter 18A, biotech listings, Greater Bay Area.

RegenXBio Secures $110M Upfront in Strategic Partnership with Nippon Shinyaku for Hunter Syndrome Gene Therapy

6 months ago talkbio0Tagged Gene, gene therapy, Mucopolysaccharidosis II, Nippon, Regenxbio, RGX-111, RGX-121, Shinyaku, strategic partnership

RegenXBio, Hunter syndrome, Gene therapy, Nippon Shinyaku, Strategic partnership, Rare metabolic disorder, Mucopolysaccharidosis type II (MPS II), RGX-121, RGX-111